Comprehensive, personalized Alpha-1 support for your patients

When you prescribe PROLASTIN-C LIQUID, your patients gain immediate access to all the benefits of the PROLASTIN DIRECT program. PROLASTIN-C LIQUID is available only through the PROLASTIN DIRECT program.

To help you get started, speak with a Patient Service Coordinator by calling 1-833-PHONEA1 (746-6321).

Have you tested your patients with COPD for alpha-1? If not, you can order your free AlphaID screening kits here.

The PROLASTIN DIRECT program simplifies Alpha-1 management for you and your patients1

A dedicated PROLASTIN-C LIQUID coordinator1

Upon enrollment, you and your patients with alpha-1 will be assigned a dedicated PROLASTIN-C LIQUID coordinator to help with all needs related to alpha-1 treatment.1

PROLASTIN DIRECT insurance specialists1

PROLASTIN DIRECT insurance specialists, who have a >90% success rate in obtaining patient coverage, will provide hands-on management of the prior authorization process.1

Specialty pharmacy and infusion experts¹

Your PROLASTIN DIRECT Alpha-1 Care Team's specialty pharmacy and infusion experts:

  • 24/7 on-call support from specialty-trained registered nurses and pharmacists dedicated exclusively to alpha-1 care.1

Automatic enrollment in a disease management program1

As part of the PROLASTIN DIRECT program, patients are automatically enrolled in a disease-management program (AlphaNet®) where they receive one-on-one support from a treatment-experienced patient with alpha-1.1

PROLASTIN-C LIQUID is available only through the PROLASTIN DIRECT program

  1. By enrolling your patients in the PROLASTIN DIRECT program, they are automatically connected to the AlphaNet Alpha-1 Disease Management and Prevention Program (ADMAPP).
  2. ADMAPP is the only fully integrated disease-management program shown to improve patient outcomes.1,2*

Significant improvements in health outcomes after intervention year (n=878)2

Increase in the use of long-term oxygen therapy (>16 hours/day [P<0.01])2

Translates into more optimal use of oxygen therapy

Increase in the use of long-acting bronchodilator
(P<0.001)2

Translates into more optimal medication use

Reduction in exacerbations (P<0.001)2

Reduction in unscheduled physician visits (P=0.03)2

Reduction in emergency room visits (P=0.02)2

Reduction in the use of systemic steroids (P=0.02)2

*Patient outcomes are based on a 2-year study comparing outcomes in a 12-month observation period with augmentation therapy alone and a 12-month intervention period with augmentation therapy plus ADMAPP2:

  • Participants were members of AlphaNet®, a not-for-profit health management company founded by patients with alpha-1 to provide comprehensive care solely for patients with alpha-12
  • 97% of ADMAPP study participants were taking PROLASTIN® (alpha1-proteinase inhibitor [human])2

Enroll your patients in the PROLASTIN DIRECT® program

PROLASTIN-C LIQUID is available only through the PROLASTIN DIRECT program.

Enroll patients

Important Safety Information

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use

  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References

  • Data on file, PROLASTIN DIRECT program.
  • Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.